Transition appoints new clinical operations vice-president
This article was originally published in Scrip
Executive Summary
Transition Therapeutics, a biopharmaceutical company developing novel therapeutics for diseases with large markets, has appointed Laura Agensky vice-president of clinical operations. Ms Agensky has been with Transition for eight years managing the implementation of clinical trials; prior to this she held a number of clinical development roles at pharmaceutical, biotech and consulting organisations. In her new role, Ms Agensky will lead the company's clinical operations group.